Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

SELL
$13.92 - $19.5 $9,744 - $13,650
-700 Reduced 3.08%
22,000 $328,000
Q4 2023

Feb 05, 2024

BUY
$8.37 - $19.8 $189,998 - $449,460
22,700 New
22,700 $329,000

Others Institutions Holding BMEA

About Biomea Fusion, Inc.


  • Ticker BMEA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,290,600
  • Market Cap $117M
  • Description
  • Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...
More about BMEA
Track This Portfolio

Track Transcend Capital Advisors, LLC Portfolio

Follow Transcend Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Transcend Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Transcend Capital Advisors, LLC with notifications on news.